Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Anastasios Stathis, Maria Cristina Pirosa, Lorella Orsucci, Pierre Feugier, Monica Tani, Hervé Ghesquières, Gerardo Musuraca, Francesca Gaia Rossi, Francesco Merli, Romain Guièze, Emmanuel Gyan, Guido Gini, Dario Marino, Remy Gressin, Franck Morschhauser, Federica Cavallo, Francesca Palombi, Annarita Conconi, Benoît Tessoulin, Hervé Tilly, Manuela Zanni, Maria Giuseppina Cabras, Enrico Capochiani, Catello Califano, Melania Celli, Alessandro Pulsoni, Francesco Angrilli, Ubaldo Occhini, René-Olivier Casasnovas, Guillaume Cartron, Liliana Devizzi, Corinne Haioun, Anna Marina Liberati, Roch Houot, Michele Merli, Giuseppe Pietrantuono, Francesca Re, Michele Spina, Francesco Landi, Franco Cavalli, Francesco Bertoni, Davide Rossi, Nicoletta Ielmini, Elena Borgo, Stefano Luminari, Emanuele Zucca, Catherine Thieblemont
The IELSG38 trial was conducted to investigate the effects of subcutaneous (SC) rituximab on the complete remission (CR) rate and the benefits of SC maintenance in patients with extranodal marginal zone lymphoma (MZL) who received frontline treatment with chlorambucil plus rituximab. Study treatment comprised an induction phase with chlorambucil 6 mg/m2/day orally on weeks 1-6, 9-10, 13-14, 17-18, and 21-22, and rituximab 375 mg/m2 intravenously on day 1 of weeks 1-4, and 1400 mg SC on weeks 9, 13, 17, and 21...
February 22, 2024: Haematologica
#2
REVIEW
Yanhua Li, Ziqing Gao, Jianhong Zhu, Jianan Su, Pengwei Chen, Jiande Li, Min Feng
PURPOSE: Idiopathic membranous nephropathy (IMN) with moderate risk or above was recommended to receive immunosuppressive therapy. We attempted to evaluate the optimal dose of glucocorticoid when combined with evidence-proven effective immunosuppressants by network meta-analysis. METHODS: A systematic review of the literature was conducted in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from inception until January 2022. Randomized controlled trials (RCTs) in IMN limited to supportive care, glucocorticoids, cyclophosphamide, chlorambucil, calcineurin inhibitors (CNIs), and rituximab were screened...
January 2024: Curēus
#3
JOURNAL ARTICLE
Emanuele Cencini, Natale Calomino, Anna Sicuranza, Alessandro Gozzetti, Alberto Fabbri, Monica Bocchia
The management of small lymphocytic lymphoma (SLL) as chronic lymphocytic leukemia (CLL) or an indolent non-Hodgkin lymphoma is highly debated. In this single-center, real-life study, 38 SLL patients managed between 2008 and 2022 were evaluated. Overall, 26/38 cases (68.4%) needed treatment and all but one received CLL concordant therapy, including BR (9/38 cases), fludarabine, cyclophosphamide, rituximab (5/38 cases), rituximab and chlorambucil (4/38 cases), BTK inhibitors (7/38 cases) and steroid (1 case with immune thrombocytopenia)...
December 11, 2023: Journal of Chemotherapy
#4
JOURNAL ARTICLE
Chaitra Ujjani
The treatment landscape of chronic lymphocytic leukemia (CLL) has evolved considerably over the past decade due to the development of effective novel agents with varying mechanisms of action, including Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL2) inhibitors. Extrapolating upon the success of anti-CD20-directed chemoimmunotherapy, a dual-targeted approach has been explored in treatment-naive patients with CLL. Anti-CD20 monoclonal antibody combinations with BTK inhibitors as well as BCL2 inhibitors have demonstrated superiority over traditional cytotoxic chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab; bendamustine-rituximab; and obinutuzumab-chlorambucil...
December 8, 2023: Hematology—the Education Program of the American Society of Hematology
#5
Adnane Hammani, Othman Doghmi, El Mehdi Mahtat, Hicham El Maaroufi, Kamal Doghmi
Soft tissue mucosa-associated lymphoid tissue (MALT) lymphoma is a rare type of marginal zone lymphoma. Herein, we report a case of a 61-year-old patient who developed soft-tissue marginal zone lymphoma in the right arm. He was treated with rituximab-chlorambucil with good metabolic response and no evidence of disease recurrence after one year of follow-up.
November 2023: Curēus
#6
JOURNAL ARTICLE
Côme Bommier, Emanuele Zucca, Sylvie Chevret, Annarita Conconi, Grzegorz S Nowakowski, Matthew J Maurer, James R Cerhan, Catherine Thieblemont, Jerome Lambert
Extranodal marginal zone lymphoma (EMZL) has a very indolent course, and the validation of surrogate markers could accelerate novel therapies. Although prognostic markers do exist, no surrogate markers have been validated in EMZL. We hypothesized that time to complete response within 24 months (TTCR24) and complete response at 24 months (CR24) could be valid surrogate markers of progression-free survival (PFS). The IELSG19 phase 3 trial showed the advantage of double therapy (rituximab-chlorambucil) over single therapy (rituximab or chlorambucil) on PFS...
October 6, 2023: Blood
#7
JOURNAL ARTICLE
Javier Loscertales, Pau Abrisqueta-Costa, Antonio Gutierrez, José Ángel Hernández-Rivas, Rafael Andreu-Lapiedra, Alba Mora, Carolina Leiva-Farré, María Dolores López-Roda, Ángel Callejo-Mellén, Esther Álvarez-García, José Antonio García-Marco
The SRealCLL study aimed to obtain real-world evidence on the clinical characteristics and treatment patterns of patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP). Electronic health records (EHRs) from seven Spanish hospitals (January 2016-December 2018) were analyzed using EHRead® technology, based on NLP and machine learning. A total of 534 CLL patients were assessed. No treatment was detected in 270 (50.6%) patients (watch-and-wait, W&W). First-line (1L) treatment was identified in 230 (43...
August 10, 2023: Cancers
#8
JOURNAL ARTICLE
Naveen C Hegde, Ankit Kumar, Shaweta Kaundal, Lekha Saha, Pankaj Malhotra, Shankar Prinja, Deepesh Lad, Amol N Patil
Though the chronic lymphocytic leukaemia (CLL) management options in India are still limited compared to the novel drug options in resource-rich settings, the availability of less costly generics and the government health insurance scheme has enabled many patients to access the newer drugs in India. The current study compared the cost-effectiveness and cost-utility of existing initial management options for the progression-free survival (PFS) time horizon from the patient's perspective. A two-health-state, PFS and progressive disease, Markov model was assumed for three regimens (generics): ibrutinib monotherapy, bendamustine-rituximab (B-R), and rituximab-chlorambucil (RClb) used as the frontline treatment of CLL patients in India...
July 13, 2023: Annals of Hematology
#9
REVIEW
Markus Raderer, Barbara Kiesewetter, Ming-Qing Du
Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) is among the more common types of lymphoma accounting for up to 8% of newly diagnosed lymphoma cases. As opposed to other B-cell lymphomas, however, no predominant genetic hallmark has been defined in MALT lymphoma, but different localizations appear to be affected by different, sometimes distinct changes. Nonetheless, a high proportion of these genetic changes reported in MALT lymphomas dysregulate the pathways leading to NF-kB activation...
2023: Therapeutic Advances in Medical Oncology
#10
JOURNAL ARTICLE
Prerika Nehra, Akashdeep Singh Chauhan, Pankaj Malhotra, Lalit Kumar, Ashish Singh, Nidhi Gupta, Nikita Mehra, Anisha Mathew, Amal Chandra Kataki, Sudeep Gupta, Shankar Prinja
BACKGROUND: Over the years, there has been introduction of newer drugs, like bendamustine and ibrutinib, for the management of chronic lymphocytic leukaemia (CLL). Though these drugs lead to better survival, they are also associated with higher cost. The existing evidence on cost effectiveness of these drugs is from high-income countries, which has limited generalisability for low-income and middle-income counties. Therefore, the present study was undertaken to assess the cost-effectiveness of three therapeutic regimens, chlorambucil plus prednisolone (CP), bendamustine plus rituximab (BR) and ibrutinib for CLL treatment in India...
June 2023: Lancet Reg Health Southeast Asia
#11
JOURNAL ARTICLE
Jung Sun Kim, Tae Min Kim, Myoung Joo Kang, Sung Ae Koh, Hyunkyung Park, Seung-Hyun Nam, Jae Joon Han, Gyeong-Won Lee, Young Jin Yuh, Hee Jeong Lee, Jung Hye Choi
BACKGROUND/AIMS: Little attention is paid to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Korea due to the rarity of the disease. With its rising incidence, we aimed to evaluate recent changes in treatment patterns and survival outcomes of patients with CLL/SLL. METHODS: A total of 141 patients diagnosed with CLL/SLL between January 2010 and March 2020 who received systemic therapy were analyzed in this multicenter retrospective study. RESULTS: The median patient age was 66 years at diagnosis, and 68...
June 26, 2023: Korean Journal of Internal Medicine
#12
JOURNAL ARTICLE
Matilde Slot, Carsten Utoft Niemann, Lars Holger Ehlers, Emelie C Rotbain
Several targeted treatments, such as venetoclax + obinutuzumab (VenO) and ibrutinib, have emerged to treat treatment-naïve patients with chronic lymphocytic leukemia (CLL) and have been shown to improve progression-free survival (PFS) compared to chlorambucil + obinutuzumab (ClbO). However, novel targeted agents are associated with a significant cost investment. The objective of this study was to investigate the cost-effectiveness of VenO compared to ClbO and ibrutinib in treatment-naïve CLL without del17p/TP53 mutation in Denmark...
May 15, 2023: Blood Advances
#13
Ester Lovato, Concetta Gangemi, Mauro Krampera, Carlo Visco, Isacco Ferrarini
Membranous glomerulonephritis (MGN) is a rare extra-hematological autoimmune complication of chronic lymphocytic leukemia (CLL), clinically characterized by nephrotic-range proteinuria and, less frequently, renal failure. Because of the rarity of this condition, there is no standardized treatment. Chlorambucil and fludarabine-based regimens, possibly combined with rituximab, have been historically the most frequent therapeutic approaches, with renal response obtained in about two-third of the patients. However, responses are often transient and partial...
2023: Frontiers in Oncology
#14
JOURNAL ARTICLE
Francesca Castellani, Andrea Visentin, Erika Schirinzi, Alessandro Salvalaggio, Mario Cacciavillani, Cinzia Candiotto, Claudia Baratè, Alessandro Cellini, Roberta Bertorelle, Gabriele Siciliano, Livio Trentin, Chiara Briani
BACKGROUND AND OBJECTIVES: Neuropathy with antibodies to myelin-associated glycoprotein (MAG) is the most common paraproteinemic IgM neuropathy. Recently, the mutational profile of the MYD88 and CXCR4 genes has been included in the diagnostic workup of IgM monoclonal gammopathies. The objective of our study was to assess the prevalence of MYD88 L265P and CXCR4 S338X gene variants in patients with anti-MAG antibody neuropathy. Secondary aims were to evaluate possible correlations between the mutational profile and neuropathy severity, antibody titers, and treatment response...
July 2023: Neurology® Neuroimmunology & Neuroinflammation
#15
JOURNAL ARTICLE
Noomi Vainer, Kathrine Aarup, Michael Asger Andersen, Lise Wind-Hansen, Tine Nielsen, Henrik Frederiksen, Lisbeth Enggaard, Christian Bjørn Poulsen, Carsten U Niemann, Emelie C Rotbain
For chronic lymphocytic leukaemia (CLL), targeted drugs have become the standard of care, in particular for second-line treatment. In this study, overall survival (OS), treatment-free survival (TFS) and adverse events (AE) were registered retrospectively in a Danish population-based cohort upon second-line treatment for CLL. Data were collected from medical records and the Danish National CLL register. For 286 patients receiving second-line treatment, three-year TFS was higher upon targeted treatment (ibrutinib/venetoclax/idelalisib) [63%, 95% confidence interval (CI) 50%-76%] compared with fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab (FCR/BR) (37%, CI: 26%-48%) and chlorambucil+/-CD20-antibody (CD20Clb/Clb) (22%, CI: 10%-33%)...
March 10, 2023: British Journal of Haematology
#16
REVIEW
Immunosuppressive treatment for idiopathic membranous nephropathy: An updated network meta-analysis.
Neng Bao, Mingjia Gu, Xiang Yu, Jin Wang, Leiping Gao, Zhiwei Miao, Wei Kong
This network meta-analysis (NMA) aims to investigate the efficacy and safety of different pharmacological treatments for idiopathic membranous nephropathy (IMN). Thirty-four relevant studies were extracted from PubMed, Embase, Cochrane database, and MEDLINE. Treatment with tacrolimus (TAC), cyclophosphamide (CTX), mycophenolate mofetil, chlorambucil (CHL), cyclosporin A (CSA), steroids, rituximab (RTX), and conservative therapy were compared. Outcomes were measured using remission rate and incidence of side effects...
2023: Open Life Sciences
#17
JOURNAL ARTICLE
Anuja Chatterjee, Gijs van de Wetering, Ron Goeree, Carolyn Owen, Anne Marie Desbois, Stephane Barakat, Beenish S Manzoor, Kavita Sail
BACKGROUND: Venetoclax is a first-in-class targeted therapy option that is an inducer of apoptosis in chronic lymphocytic leukemia (CLL) cells. The open-label phase III CLL14 clinical trial showed that venetoclax combined with obinutuzumab (VEN+O) is superior to obinutuzumab combined with chlorambucil in newly diagnosed patients with CLL. The aim of this study was to assess the health economic value of VEN+O for the frontline treatment of CLL in Canada from a publicly funded healthcare system perspective...
November 5, 2022: PharmacoEconomics Open
#18
JOURNAL ARTICLE
Andrea Messori
OBJECTIVE: In chronic lymphocytic leukemia, growing evidence has accumulated about long-term outcomes of first-line treatments. Our objective was to perform indirect comparisons across first-line treatments. METHODS: We applied the Shiny method, an artificial intelligence technique that analyses Kaplan-Meier curves and reconstructs patient-level data. Reconstructed patient data were then evaluated through standard survival statistics and indirect head-to-head comparisons...
January 2023: European Journal of Haematology
#19
JOURNAL ARTICLE
Estela Moreno-Martínez, Javier De la Serna-Torroba, Vicente Escudero-Vilaplana, José Ángel Hernández-Rivas, Marina Sánchez-Cuervo, Raquel Sánchez-Hernández
OBJECTIVE: Venetoclax in combination with obinutuzumab has significantly improved efficacy versus immunochemotherapy (progression-free survival) in patients with chronic lymphocytic leukaemia who have not received prior treatment. The objective of this study was to evaluate its efficiency in Spain using a cost-utility analysis. METHOD: Using a partitioned-survival analysis model adapted to the Spanish context and based on three health states (progression-free survival, survival after progression, and death), a simulation of the evolution of patients who were candidates for initiating first-line treatment was conducted for a lifetime time horizon...
April 27, 2022: Farmacia Hospitalaria
#20
REVIEW
Miguel Arguello-Tomas, Nil Albiol, Paola Jara, Jordi Sierra, Alba Mora, Carol Moreno
CONTEXT: The treatment of chronic lymphocytic leukemia (CLL) has dramatically evolved over the last decade thanks to the introduction of the targeted therapies. Nowadays, international guidelines (ESMO 2021, NCCN 2022) recommend targeted therapies including BTKi and BCL2i combinations as the preferred regimens for the treatment of most treatment naïve CLL patients. OBJECTIVE: To describe pattern changes in the front-line treatment in CLL patients. DESIGN: This is a retrospective, single center, and non-interventional study...
October 2022: Clinical Lymphoma, Myeloma & Leukemia
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
